New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 3, 2014
07:37 EDTMYGNMyriad Genetics price target raised to $40 from $28 at Mizuho
Mizuho raised Myriad's price target to $40 from $28 following the better than expected CMS pricing for BRCA testing. Shares are Neutral rated.
News For MYGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 1, 2015
07:16 EDTMYGNMyriad Genetics issued U.S. patent for Vectra DA
Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, announced that the United States Patent and Trademark Office has issued United States Patent No. 9,200,324. The patent, which is expected to expire in 2031, provides intellectual property protection for Crescendo Bioscience's Vectra DA testing. The recently issued patent is co-assigned to Crescendo and the Oklahoma Medical Research Foundation and is the first patent issued relating to Vectra DA.
November 27, 2015
10:44 EDTMYGNCMS may have made mistake with Myriad BRCA pricing, says Piper Jaffray
Piper Jaffray analyst William Quirk noted that the Centers for Medicare and Medicaid Services, or CMS, released the final 2016 Clinical Diagnostic Laboratory Fee Schedule yesterday, which showed Myriad Genetics' BRCA1/2 sequencing and full duplication/deletion analysis priced at $1,839.54, down from the $2,483.37 listed in the preliminary and final CLFS determination documents. Quirk said this may be an error and that he anticipates CMS to issue a correction and/or Myriad to file an appeal in the near-term. The analyst keeps an Overweight rating on Myriad shares.
November 23, 2015
05:36 EDTMYGNGenomic Health upgraded to Buy from Neutral at UBS
Subscribe for More Information
November 19, 2015
07:19 EDTMYGNCMS decision a big positive for Myriad Genetics, says Stephens
Subscribe for More Information
November 18, 2015
09:49 EDTMYGNCMS reversal removes 'huge overhang' for CareDx, says Mizuho
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use